National cooperative group trial seeks to cut in half early mortality rates for rare leukemia
(Medical College of Georgia at Augusta University) A national cooperative group trial is making a handful of the country's experts in a rare leukemia available around the clock, with the goal of cutting by more than half the high mortality rates that occur in the difficult first few weeks of treatment.Induction mortality for treatment of acute promyelocytic leukemia, or APL, can be as high as 30 percent, but for patients who survive those first few weeks, survival rates can soar beyond 90 percent, making it the most curable leukemia.
Authors: Liu RT, Wang XX, Sun JR, Gao N, Yu WZ Abstract OBJECTIVE: The aim of this study was to investigate the correlations between interleukin-6 (IL-6) and IL-10 gene polymorphisms with childhood acute lymphoblastic leukemia. PATIENTS AND METHODS: Specimens were collected from 200 children with acute lymphoblastic leukemia (disease group) and 200 normal children (control group) in our hospital. DNA was extracted from peripheral blood nucleated cells in both groups to detect the gene polymorphisms rs2069830 and rs2069836 of IL-6, as well as rs3024489 and rs3024493 of IL-10. Then, the content of serum IL-6 and ...
Publication date: Available online 16 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae
Authors: Abstract [This retracts the article on p. 5739 in vol. 8, PMID: 26191290.]. PMID: 32782725 [PubMed - in process]
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy
Conditions: B-ALL; DLBCL; B ALL; Dlbcl-Ci; DLBCL Unclassifiable; DLBCL, Nos Genetic Subtypes; DLBCL Activated B-Cell Type; DLBCL Germinal Center B-Cell Type; Diffuse Large B-cell Lymphoma; HGBL; HGBL, Nos Interventions: Drug: 131-I Apamistamab; Biological: CAR T-cell Sponsors: Memorial Sloan Kettering Cancer Center; Actinium Pharmaceuticals Not yet recruiting
Conditions: Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; AML, Adult; CLL; CLL, Relapsed; CLL, Refractory Interventions: Drug: Pitavastatin; Drug: Venetoclax Sponsors: University of California, Irvine; United States Department of Defense Not yet recruiting
Authors: Patel A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Normolle D, Lontos K, Boyiadzis M PMID: 32753091 [PubMed - as supplied by publisher]
Publication date: Available online 12 August 2020Source: Pharmacology &TherapeuticsAuthor(s): Wencheng Xu, Shuhe Chen, Xiaoqin Wang, Sachiko Tanaka, Kenji Onda, Kentaro Sugiyama, Haruki Yamada, Toshihiko Hirano
Publication date: Available online 10 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Cyril Šálek, Jan Vydra, Ela Cerovská, Šárka Šestáková, Šárka Ransdorfová, Veronika Válková, Petr Cetkovský, Hana Remešová
Publication date: Available online 6 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lei Deng, Changjian Zhang, Sunyang Ying, Bo Cai, Fang Zhou